Signaling from G Protein-coupled Receptors to the c-jun Promoter Involves the MEF2 Transcription Factor

EVIDENCE FOR A NOVEL c-Jun AMINO-TERMINAL KINASE-INDEPENDENT PATHWAY*

Abstract

The c-Jun amino-terminal kinases (JNKs) are a subfamily of mitogen-activated protein kinases that phosphorylate c-Jun and ATF2, and it has been postulated that phosphorylated c-Jun enhances its own expression through AP-1 sites on the c-junpromoter. In this study, we asked whether signals activating JNK regulate the c-jun promoter. Using NIH 3T3 cells expressing G protein-coupled m1 acetylcholine receptors as an experimental model, we have recently shown that the cholinergic agonist carbachol, but not platelet-derived growth factor, potently elevates JNK activity. Consistent with these findings, carbachol, but not platelet-derived growth factor, increased the activity of a c-jun promoter-driven reporter gene (for chloramphenicol acetyltransferase). However, coexpression of JNK kinase kinase (MEKK) effectively increased JNK activity, but resulted in surprisingly limited induction of the c-junpromoter. This raised the possibility that pathway(s) distinct from JNK control the c-jun promoter, and prompted us to explore which of its regulatory elements participate in transcriptional control. We observed that deletion of the 3′ AP-1 site diminished chloramphenicol acetyltransferase activity in response to carbachol, but only to a limited extent. In contrast, deletion of a MEF2 site dramatically reduced expression, and deletion of both the MEF2 and 3′ AP-1 sites abolished induction. Furthermore, cotransfection with MEF2C and MEF2D cDNAs potently enhanced the activity of the c-jun promoter in response to carbachol, and stimulation of m1 receptors, but not direct JNK activation, induced expression of a MEF2-responsive plasmid. Taken together, these data strongly suggest that MEF2 mediates c-jun promoter expression by G protein-coupled receptors through a yet to be identified pathway, distinct from that of JNK.

Footnotes

  • * The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • § Supported by the Howard Hughes Medical Institute as a National Institutes of Health Research Scholar.

  • ** To whom correspondence should be addressed: Molecular Signaling Unit, Oral and Pharyngeal Cancer Branch, NIDR, NIH, 9000 Rockville Pike, Bldg. 30, Rm. 212, Bethesda, MD 20892-4330. Fax: 301-402-0823.

  • 1 The abbreviations used are: TPA, 12-O-tetradecanoylphorbol-13-acetate; TRE, TPA-responsive element; MAPK, mitogen-activated protein kinase; JNK, c-Jun amino-terminal kinase; mAChR, muscarinic acetylcholine receptor; PDGF, platelet-derived growth factor; CAT, chloramphenicol acetyltransferase; DMEM, Dulbecco’s modified Eagle’s medium; MEKK, JNK kinase kinase; MEKEE, constitutively active mutant of MEK; MEK, MAP kinase kinase; MEF, myocyte enhancer family.

    • Received December 10, 1996.
    • Revision received May 30, 1997.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement